These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 11929787)

  • 1. The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
    He Y; Wertheim JA; Xu L; Miller JP; Karnell FG; Choi JK; Ren R; Pear WS
    Blood; 2002 Apr; 99(8):2957-68. PubMed ID: 11929787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.
    Roumiantsev S; de Aos IE; Varticovski L; Ilaria RL; Van Etten RA
    Blood; 2001 Jan; 97(1):4-13. PubMed ID: 11133737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
    Zhang X; Subrahmanyam R; Wong R; Gross AW; Ren R
    Mol Cell Biol; 2001 Feb; 21(3):840-53. PubMed ID: 11154271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity.
    Li S; Ilaria RL; Million RP; Daley GQ; Van Etten RA
    J Exp Med; 1999 May; 189(9):1399-412. PubMed ID: 10224280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
    McWhirter JR; Galasso DL; Wang JY
    Mol Cell Biol; 1993 Dec; 13(12):7587-95. PubMed ID: 8246975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Grb2 binding site is required for the induction of chronic myeloid leukemia-like disease in mice by the Bcr/Abl tyrosine kinase.
    Million RP; Van Etten RA
    Blood; 2000 Jul; 96(2):664-70. PubMed ID: 10887132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow.
    Pear WS; Miller JP; Xu L; Pui JC; Soffer B; Quackenbush RC; Pendergast AM; Bronson R; Aster JC; Scott ML; Baltimore D
    Blood; 1998 Nov; 92(10):3780-92. PubMed ID: 9808572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
    Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
    Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
    Gross AW; Zhang X; Ren R
    Mol Cell Biol; 1999 Oct; 19(10):6918-28. PubMed ID: 10490629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
    Bai RY; Jahn T; Schrem S; Munzert G; Weidner KM; Wang JY; Duyster J
    Oncogene; 1998 Aug; 17(8):941-8. PubMed ID: 9747873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector.
    Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T
    J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
    Shuai K; Halpern J; ten Hoeve J; Rao X; Sawyers CL
    Oncogene; 1996 Jul; 13(2):247-54. PubMed ID: 8710363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
    Million RP; Aster J; Gilliland DG; Van Etten RA
    Blood; 2002 Jun; 99(12):4568-77. PubMed ID: 12036890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
    Zhang X; Wong R; Hao SX; Pear WS; Ren R
    Blood; 2001 Jan; 97(1):277-87. PubMed ID: 11133772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RhoGEF domain of p210 Bcr-Abl activates RhoA and is required for transformation.
    Sahay S; Pannucci NL; Mahon GM; Rodriguez PL; Megjugorac NJ; Kostenko EV; Ozer HL; Whitehead IP
    Oncogene; 2008 Mar; 27(14):2064-71. PubMed ID: 17922031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products.
    Allen PB; Morgan GJ; Wiedemann LM
    Baillieres Clin Haematol; 1992 Oct; 5(4):897-930. PubMed ID: 1308169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
    Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G
    Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a cell line with variant BCR/ABL breakpoint expressing P180BCR/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia.
    Inokuchi K; Shinohara T; Futaki M; Hanawa H; Tanosaki S; Yamaguchi H; Nomura T; Dan K
    Genes Chromosomes Cancer; 1998 Nov; 23(3):227-38. PubMed ID: 9790503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
    LaMontagne KR; Flint AJ; Franza BR; Pandergast AM; Tonks NK
    Mol Cell Biol; 1998 May; 18(5):2965-75. PubMed ID: 9566916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.